Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
Search
Our_Inflammatory_Disease_Research.pdf
CardioMetabolic_diseases.pdf
Cardiometabolic_Diseases.pdf
Central_Nervous_System_Diseases.pdf
The Global Cardiovascular Disease Burden.pdf
The Global Cardiovascular Disease Burden.pdf
Kidney_Disease_in_Type_2_Diabetes.pdf
stargardt_disease_infographic.pdf
Partnering in Cardiometabolic Diseases MAY 2023 Corp
Cardiovascular Disease
Chronic Obstructive Pulmonary Disease
Cardiovascular renal and metabolic diseases infographic
ACCESSIBLE_Stargardt_Disease
Stargardt_Disease
Animal Health Partnering Interests Cardiometabolic Diseases May 2024 CORP
Animal Health Partnering Interests Infectious Diseases May 2024 CORP
Animal Health Partnering Interests CNS Diseases May 2024 CORP
Partnering in Infectious Diseases MAY 2024 CORP_0.pdf
Partnering in Cardiometabolic Diseases MAY 2024 CORP_0.pdf
Partnering in CNS Diseases MAY 2024 CORP_0.pdf
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
Advances in vectored vaccines for poultry
Vaccine design technologies have made huge advances in recent years. One of the newer categories of vaccine, vectored vaccines, is overcoming challenges that conventional vaccines do not meet.
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.